{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m deucravacitinib
to a specific field?
Status:
Possibly Marketed Outside US
Source:
NCT01686698: Phase 4 Interventional Completed Cirrhosis
(2013)
Source URL:
First approved in 2023
Source:
weight loss gummies by XIAN CHIANG COMPANY LIMITED
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Digestive Patch by Guangzhou Hanhai Trading Co., Ltd
(2023)
Source URL:
First approved in 2023
Source:
Digestive Patch by Guangzhou Hanhai Trading Co., Ltd
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125748
(2022)
Source URL:
First approved in 2022
Source:
BLA125748
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
antiseptic solution by Anhui Cao coral biology science and technology co., ltd
(2022)
Source URL:
First approved in 2022
Source:
antiseptic solution by Anhui Cao coral biology science and technology co., ltd
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M017
(2022)
Source URL:
First approved in 2022
Source:
M017
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Soothing Apricot Toner by Acheson & Acheson Ltd.
(2021)
Source URL:
First approved in 2021
Source:
Soothing Apricot Toner by Acheson & Acheson Ltd.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03355846: Phase 4 Interventional Completed Acute Anal Fissure
(2018)
Source URL:
First approved in 2021
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
IMUBOLIC by Ayurax
(2022)
Source URL:
First approved in 2021
Source:
NMN.5S by Chengdu Heqi Cosmetics Co., Ltd
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03530124: Phase 4 Interventional Completed Apnea
(2018)
Source URL:
First approved in 2021
Source:
Jointox BB by Energique, Inc.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class:
STRUCTURALLY DIVERSE